Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) EPS (Weighted Average and Diluted) (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed EPS (Weighted Average and Diluted) for 2 consecutive years, with $1.75 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 144.08% to $1.75 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7, a 197.44% increase, with the full-year FY2025 number at -$0.23, up 98.76% from a year prior.
  • EPS (Weighted Average and Diluted) was $1.75 for Q4 2025 at Neuphoria Therapeutics, up from -$4.41 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $6.55 in Q1 2025 to a low of -$4.41 in Q3 2025.